Applicability of the European Commission's framework on safe and sustainable by design to the pharmaceutical sector

Neele Puhlmann; Elisabetta Abbate; Klaus Kümmerer; Agnes G. Oomen; Ad M.J. Ragas; Caroline Moermond

doi:10.1016/j.scp.2024.101845

Applicability of the European Commission's framework on safe and sustainable by design to the pharmaceutical sector

Publikation: Beiträge in Zeitschriften › Übersichtsarbeiten › Forschung

Standard

Applicability of the European Commission's framework on safe and sustainable by design to the pharmaceutical sector. / Puhlmann, Neele; Abbate, Elisabetta; Kümmerer, Klaus et al.
in: Sustainable Chemistry and Pharmacy, Jahrgang 42, 101845, 12.2024.

Publikation: Beiträge in Zeitschriften › Übersichtsarbeiten › Forschung

Bibtex

@article{b5106c27641a48188656e2dd92785d57,

title = "Applicability of the European Commission's framework on safe and sustainable by design to the pharmaceutical sector",

abstract = "The chemical sector contributes significantly to anthropogenic impacts on planetary health. Thus, there is a need for a green transformation. The same holds for the pharmaceutical sector. To assist with this transformation, European Commission's Joint Research Centre (JRC) developed a framework on Safe and Sustainable by Design (SSbD) for chemicals and materials (“SSbD framework”). The general structure of the SSbD framework leaves room for sector-specific priorities and practices. This study explores the applicability of the SSbD framework to the pharmaceutical sector; more specifically to the development, production and use of Human Medicinal Products (HMPs). We show that the stage-gate process in R&D of HMPs fits very well with the design-assessment process of the SSbD framework, making the framework conceptually applicable to pharmaceutical R&D. Future efforts should focus on the development of i) methods to predict environmental safety and sustainability based on the limited data available during R&D, ii) a pragmatic procedure integrating SSbD into HMPs innovation, and iii) a weighing system considering also environmental safety and sustainability parameters alongside patient safety and medical efficacy. Although the assessment phase of the JRC's SSbD framework has specifically been developed for innovation purposes, we propose an expansion of its scope to pharmaceutical products already on the market. The reason is its applicability by healthcare actors to guide safer and more sustainable choices regarding the use of marketed HMPs. We call this approach Safe and Sustainable by Comparison (SSbC) and show that the assessment principles of the SSbD framework can be applied to SSbC.",

keywords = "Green, Health, Innovation, Lifecyle, Chemistry, Higher Education and Science Management",

author = "Neele Puhlmann and Elisabetta Abbate and Klaus K{\"u}mmerer and Oomen, {Agnes G.} and Ragas, {Ad M.J.} and Caroline Moermond",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2024",

month = dec,

doi = "10.1016/j.scp.2024.101845",

language = "English",

volume = "42",

journal = "Sustainable Chemistry and Pharmacy",

issn = "2352-5541",

publisher = "Elsevier B.V.",

}

RIS

TY - JOUR

T1 - Applicability of the European Commission's framework on safe and sustainable by design to the pharmaceutical sector

AU - Puhlmann, Neele

AU - Abbate, Elisabetta

AU - Kümmerer, Klaus

AU - Oomen, Agnes G.

AU - Ragas, Ad M.J.

AU - Moermond, Caroline

PY - 2024/12

Y1 - 2024/12

N2 - The chemical sector contributes significantly to anthropogenic impacts on planetary health. Thus, there is a need for a green transformation. The same holds for the pharmaceutical sector. To assist with this transformation, European Commission's Joint Research Centre (JRC) developed a framework on Safe and Sustainable by Design (SSbD) for chemicals and materials (“SSbD framework”). The general structure of the SSbD framework leaves room for sector-specific priorities and practices. This study explores the applicability of the SSbD framework to the pharmaceutical sector; more specifically to the development, production and use of Human Medicinal Products (HMPs). We show that the stage-gate process in R&D of HMPs fits very well with the design-assessment process of the SSbD framework, making the framework conceptually applicable to pharmaceutical R&D. Future efforts should focus on the development of i) methods to predict environmental safety and sustainability based on the limited data available during R&D, ii) a pragmatic procedure integrating SSbD into HMPs innovation, and iii) a weighing system considering also environmental safety and sustainability parameters alongside patient safety and medical efficacy. Although the assessment phase of the JRC's SSbD framework has specifically been developed for innovation purposes, we propose an expansion of its scope to pharmaceutical products already on the market. The reason is its applicability by healthcare actors to guide safer and more sustainable choices regarding the use of marketed HMPs. We call this approach Safe and Sustainable by Comparison (SSbC) and show that the assessment principles of the SSbD framework can be applied to SSbC.

AB - The chemical sector contributes significantly to anthropogenic impacts on planetary health. Thus, there is a need for a green transformation. The same holds for the pharmaceutical sector. To assist with this transformation, European Commission's Joint Research Centre (JRC) developed a framework on Safe and Sustainable by Design (SSbD) for chemicals and materials (“SSbD framework”). The general structure of the SSbD framework leaves room for sector-specific priorities and practices. This study explores the applicability of the SSbD framework to the pharmaceutical sector; more specifically to the development, production and use of Human Medicinal Products (HMPs). We show that the stage-gate process in R&D of HMPs fits very well with the design-assessment process of the SSbD framework, making the framework conceptually applicable to pharmaceutical R&D. Future efforts should focus on the development of i) methods to predict environmental safety and sustainability based on the limited data available during R&D, ii) a pragmatic procedure integrating SSbD into HMPs innovation, and iii) a weighing system considering also environmental safety and sustainability parameters alongside patient safety and medical efficacy. Although the assessment phase of the JRC's SSbD framework has specifically been developed for innovation purposes, we propose an expansion of its scope to pharmaceutical products already on the market. The reason is its applicability by healthcare actors to guide safer and more sustainable choices regarding the use of marketed HMPs. We call this approach Safe and Sustainable by Comparison (SSbC) and show that the assessment principles of the SSbD framework can be applied to SSbC.

KW - Green

KW - Health

KW - Innovation

KW - Lifecyle

KW - Chemistry

KW - Higher Education and Science Management

UR - http://www.scopus.com/inward/record.url?scp=85208686547&partnerID=8YFLogxK

U2 - 10.1016/j.scp.2024.101845

DO - 10.1016/j.scp.2024.101845

M3 - Scientific review articles

AN - SCOPUS:85208686547

VL - 42

JO - Sustainable Chemistry and Pharmacy

JF - Sustainable Chemistry and Pharmacy

SN - 2352-5541

M1 - 101845

ER -